A'youth' pill aimed at reversing the damage done by dementia and other age-related diseases could undergo human trials within two years, it has been revealed. The pill is based on a blend of thirty vitamins and minerals widely available in health food stores - and will be taken as a dietary supplement. Early tests of the formula, which contains common ingredients such as vitamins B, C and D, folic acid, green tea extract, cod liver oil, have been'dramatic,' scientists say. They believe it could someday slow the progress of catastrophic neurological diseases such as Alzheimer's and Parkinson's. A series of studies published over the last decade and a half have shown its benefits in mice.
A drug that can reverse aspects of ageing has been successfully trialled in animals, say scientists. They have rejuvenated old mice to restore their stamina, coat of fur and even some organ function. The team at Erasmus University Medical Center, in the Netherlands, are planning human trials for what they hope is a treatment for old age. A UK scientist said the findings were "impossible to dismiss", but that unanswered questions remained. The approach works by flushing out retired or "senescent" cells in the body that have stopped dividing.
Since humans first realised we were doomed to die, we've sought immortality – through religion, great works or producing children to carry our selfish genes into the future. And then there are those who believe death is for other people. According to Orbis Research, consumers spent $43 billion (£33 billion) on anti-ageing products in 2018 – from lactic-acid-based anti-wrinkle creams to collagen peptide tablets and anti-oxidant co-enzyme Q10 pills. Research from Pitchbook estimates that $559 million in venture capital was invested in US anti-ageing companies in 2017. These include California-based BioTime, which is developing treatments using embryonic stem cells to rebuild cell and tissue function; CohBar, working on editing the mitochondrial genome to regulate metabolism and cell death; and Google sister company Calico, which has a $2.5 billion budget for research into solutions for age-related diseases.
In the early 2000s a group of scientists at Stanford University, California, revived a grisly procedure used in the 1950s known as parabiosis. They paired living mice, young with old, peeled back their skin and stitched together their sides so the two animals shared the same blood circulatory system. A month later, they found signs of rejuvenation in the muscles and livers of the old mice. The findings, published in 2005, turned the minds of scientists, entrepreneurs and the public to the potential of young blood to rejuvenate ageing people. By 2016, enough interest had grown to prompt a US-based startup called Ambrosia to start offering pricey infusions of young plasma – the cell-free component of blood.